1112 related articles for article (PubMed ID: 28229191)
101. Recurrent Marginal Zone Lymphoma with Bone Marrow Involvement Detected by ¹⁸F-FDG PET/CT and Biopsy: A Diagnostic Challenge.
Hsiao YS; Shen SC; Hsiao SC
Am J Case Rep; 2024 Apr; 25():e943275. PubMed ID: 38644602
[TBL] [Abstract][Full Text] [Related]
102. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
[TBL] [Abstract][Full Text] [Related]
103. Positron Emission Tomography-based Analysis Can Accurately Predict Bone Marrow Involvement With Mantle Cell Lymphoma.
Morgan R; Perry M; Kwak J; Jensen A; Kamdar M
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):731-736. PubMed ID: 30075973
[TBL] [Abstract][Full Text] [Related]
104. Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow.
Elstrom RL; Tsai DE; Vergilio JA; Downs LH; Alavi A; Schuster SJ
Clin Lymphoma; 2004 Jun; 5(1):62-4. PubMed ID: 15245610
[TBL] [Abstract][Full Text] [Related]
105. Detection of bone marrow involvement with FDG PET/CT in patients with newly diagnosed lymphoma.
Özpolat HT; Yilmaz E; Goksoy HS; Özpolat S; Dogan Ö; Unal SN; Nalcaci M
Blood Res; 2018 Dec; 53(4):281-287. PubMed ID: 30588464
[TBL] [Abstract][Full Text] [Related]
106. Biopsy remains indispensable for evaluating bone marrow involvement in DLBCL patients despite the use of positron emission tomography.
Saiki Y; Tomita N; Uchida A; Uemura Y; Suzuki Y; Hirakawa T; Kato M; Hoshikawa M; Kawano T; Nakamura N; Miura I; Arai A
Int J Hematol; 2021 May; 113(5):675-681. PubMed ID: 33515158
[TBL] [Abstract][Full Text] [Related]
107. Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma: a special emphasis on bone marrow involvement.
Kupik O; Akin S; Tuncel M; Eren G; Türker A; Kars A; Erbaş B
Nucl Med Commun; 2020 Jun; 41(6):540-549. PubMed ID: 32209829
[TBL] [Abstract][Full Text] [Related]
108. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
Guay C; Lépine M; Verreault J; Bénard F
J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
[TBL] [Abstract][Full Text] [Related]
109. Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma.
Aide N; Talbot M; Fruchart C; Damaj G; Lasnon C
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):699-711. PubMed ID: 29214417
[TBL] [Abstract][Full Text] [Related]
110. Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation-Wide cohort study.
Ródenas-Quiñonero I; Chen-Liang T; Martín-Santos T; Salar A; Fernández-González M; Celades C; Navarro JT; Martínez-Garcia AB; Andreu R; Balaguer A; Martin García-Sancho A; Baile M; López-Jiménez J; Marquet-Palomanes J; Teruel AI; Terol MJ; Benet C; Frutos L; Navarro JL; Uña J; Suarez M; Cortes M; Contreras J; Ruiz C; Tamayo P; Mucientes J; Sopena-Novales P; Reguilón-Gallego L; Sánchez-Blanco JJ; Pérez-Ceballos E; Jerez A; Ortuño FJ
Cancer Med; 2023 Mar; 12(6):6536-6546. PubMed ID: 36373169
[TBL] [Abstract][Full Text] [Related]
111. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.
Bangerter M; Moog F; Buchmann I; Kotzerke J; Griesshammer M; Hafner M; Elsner K; Frickhofen N; Reske SN; Bergmann L
Ann Oncol; 1998 Oct; 9(10):1117-22. PubMed ID: 9834825
[TBL] [Abstract][Full Text] [Related]
112. 18f-Fluorodeoxyglucose Positron Emission Tomography Versus Bone Marrow Biopsy for the Evaluation of Bone Marrow Infiltration in Newly Diagnosed Lymphoma Patients.
Aguado-Vázquez TM; Olivas-Martínez A; Cancino-Ramos U; Zúñiga-Tamayo DA; Lome-Maldonado MDCA; Rivas-Vera S; García-Pérez FO; Candelaria-Hernández MG
Rev Invest Clin; 2020 May; 73(5):. PubMed ID: 33048916
[TBL] [Abstract][Full Text] [Related]
113. Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma.
Alkhawtani RHM; Noordzij W; Glaudemans AWJM; van Rijn RS; van der Galiën HT; Balink H; Nijland M; Adams HJA; Huls G; van Meerten T; Kwee TC
Nucl Med Commun; 2018 Jun; 39(6):572-578. PubMed ID: 29672465
[TBL] [Abstract][Full Text] [Related]
114. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
115. Prognostic value of metabolic indices and bone marrow uptake pattern on preoperative 18F-FDG PET/CT in pediatric patients with neuroblastoma.
Li C; Zhang J; Chen S; Huang S; Wu S; Zhang L; Zhang F; Wang H
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):306-315. PubMed ID: 29110068
[TBL] [Abstract][Full Text] [Related]
116. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
Liu Y
Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
[TBL] [Abstract][Full Text] [Related]
117. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis.
Chen YK; Yeh CL; Tsui CC; Liang JA; Chen JH; Kao CH
Clin Nucl Med; 2011 Jul; 36(7):553-9. PubMed ID: 21637057
[TBL] [Abstract][Full Text] [Related]
118. PET/CT: Clinical role in lymphomas.
Papathanasiou N
Hell J Nucl Med; 2023; 26 Suppl():36-37. PubMed ID: 37658560
[No Abstract] [Full Text] [Related]
119.
Yang C; Wu W; Zhou H; Zhao S; Tian R; Xiang M; Zou L
Front Oncol; 2022; 12():894804. PubMed ID: 35965550
[TBL] [Abstract][Full Text] [Related]
120. Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease.
Kabickova E; Sumerauer D; Cumlivska E; Drahokoupilova E; Nekolna M; Chanova M; Hladikova M; Kodet R; Belohlavek O
Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):1025-31. PubMed ID: 16565847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
